Is there a role for calcium channel blockers in congestive heart failure?

Current Cardiology Reports

Volumn 3, Issue 2, 2001, Pages 114-118

  Miller, Alan B ^a  

^a UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT;

CONGESTIVE HEART FAILURE; HEMODYNAMICS; HUMAN; PATHOPHYSIOLOGY; REVIEW;

CALCIUM CHANNEL BLOCKERS; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS;

EID: 0035289807     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-001-0036-7     Document Type: Article

References (23)

1. Braunwald E, Ross J Jr, Sonnenblick EH: Mechanisms of contraction of normal and failing heart, edn 2. Boston: Little, Brown; 1976:1-417.
2. Cohn JN, Archibald DG, Ziesche S, et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veteran's Administration cooperative study (V-HeFT). N Engl J Med 1986, 314:1547-1552.
3. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987, 1316:1429-1435.
4. Cohn JN, Johnson G, Ziesche S, et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303-310.
5. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fraction in congestive heart failure. N Engl J Med 1991, 325:293-302.
6. Francis GS, Cohn JN, Johnson G, et al.: Plasma norepinephrine, plasma renin activity, and congestive heart failure: relation to survival and the effects of therapy in V-HeFT II. Circulation 1993, 87:V140-V148.
7. Packer M, Carver JR, Rodeheffer RJ, et al.: Effect of oral milrinone on mortality in severe chronic heart failure: The PROMISE Study Research Group. N Engl J Med 1991, 325:1468-1475.
8. Packer M, Rouleau J, Swedberg K, et al.: Effects of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study. Circulation 1993, 88(Suppl I):I301.
9. Miller AB, Conetta DA, Bass TA: Sublingual nifedipine: acute effects on severe chronic congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 1985, 55:1355-1362.
10. Magorien RD, Leier CV, Colibash AJ, et al.: Beneficial effects of nifedipine on rest and exercise myocardial energenics in patients with congestive heart failure. Circulation 1984, 70:884-890.
11. Elkayam U, Amin J, Mehra A, et al.: A prospective randomized double-blind crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990, 82:1954-1961.
12. Packer M, Kessler PD, Lee WH: Calcium channel blockade in the management of severe chronic congestive heart failure: a bridge too far. Circulation 1987, 75(Suppl V):V56-V64.
13. Packer M, Nicod P, Khandheria BR, et al.: Randomized multicenter double blind placebo controlled evaluation of amlodipine in patients with mild to moderate heart failure. J Am Coll Cardiol 1991, 17(Suppl A):274A.
14. Packer M, O'Connor CM, Ghali JK, et al.: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996, 335:1107-1114.
15. Packer M, Miller AB: Can physicians always explain the results of clinical trials? A case study of amlodipine and heart failure. Am J Cardiol 1999, 84:1L-33L.
16. Cohn JN, Ziesche S, Smith R, et al.: Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril - V-HeFT III. Circulation 1997, 96:856-863.
17. Lavine TB, Bernink JLM, Caspi A, et al.: Effect of mibefradil, a T-type calcium channel blocker on morbidity and mortality in moderate to severe congestive heart failure. Circulation 2000, 101:758-764.
18. Packer M: Prospective randomized amlodipine survival evaluation 2. Presentation American College of Cardiology. Anaheim, CA; March 2000.
19. MERIT - HF study group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure. Lancet 1999, 353:2001-2006.
20. CIBIS - II investigators and committees: The Cardiac Insufficiency Bisoprolol Study II: a randomized trial. Lancet 1999, 353:9-13.
21. Packer M, Bristow MR, Cohn JN, et al.: Effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996, 334:1349-1355.
22. Mason RP, Walter MF, Trumbore MW, et al.: Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 1999, 31:275-281.
23. Yue TL, McKenna PJ, Lysko PG, et al.: SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant. Eur J Pharmacol 1994, 251:237-243.